INFevo Raises Over RMB 100M Pre-A to Expand AI Virtual-Cell Research

What happened
On November 16, 2026, INFevo announced it had raised over RMB 100 million in a Pre-A funding round. The investment will be used to develop its AI-based virtual-cell models and automated laboratory systems. The round was led by Xinglian Capital and included several other investors, with participation from both new and existing backers. This follows an angel round in June 2026 and sets a record for single-round financing among Chinese virtual-cell startups.
Key details
- Funding amount exceeds RMB 100 million in Pre-A round.
- Investors include Xinglian Capital, Prosperity7 Ventures, Huagai Capital, Huakong Fund, DT Capital, Shunwei Capital, HSG, and Songhe Capital.
- Previous angel round raised tens of millions of yuan in June 2026.
- INFevo's virtual-cell models aim to predict cellular responses to drugs or genetic changes.
- The company is collaborating with Peking University First Hospital on tumor organoid research.
Why it matters
Pharmaceutical companies, hospitals, and research institutions working with INFevo will have access to improved tools for predicting drug responses and designing experiments. The new funding allows INFevo to expand both its computational prediction models and automated laboratory validation systems, potentially speeding up drug discovery and research workflows. This record-setting investment gives INFevo resources to further integrate AI predictions with clinical and experimental data, directly impacting how new therapies are developed and tested in China.
